CAJ | 학술논문

目的：研究非小细胞肺癌(NSCLC)患者化疗过程中血清同型半胱胺酸(Hcy)水平的变化,探讨其动态监测在化疗疗效预测中的临床价值。方法选取该院 NSCLC 化疗患者62例,研究患者化疗过程中检测血清 Hcy、癌胚抗原(CEA)和细胞角蛋白19片段(CYFRA21-1)水平,结合患者病理分型对检测结果进行统计学分析。结果化疗有效组血清三项指标与化疗前相比均呈下降趋势,且差异均有统计学意义(P <0.05),Hcy 水平在化疗一个周期后变化有统计学意义(P <0.05)；化疗无效组中三项指标化疗后与化疗前相比有所变化,但差异均无统计学意义(P >0.05)；三项指标在单独肺鳞癌及肺腺癌中的阳性率差异有统计学意义(P <0.05)。结论NSCLC 患者化疗过程中监测血清 Hcy 水平的变化,有助于观察患者病情动态变化、评估患者化疗疗效。
목적：연구비소세포폐암(NSCLC)환자화료과정중혈청동형반광알산(Hcy)수평적변화,탐토기동태감측재화료료효예측중적림상개치。방법선취해원 NSCLC 화료환자62례,연구환자화료과정중검측혈청 Hcy、암배항원(CEA)화세포각단백19편단(CYFRA21-1)수평,결합환자병리분형대검측결과진행통계학분석。결과화료유효조혈청삼항지표여화료전상비균정하강추세,차차이균유통계학의의(P <0.05),Hcy 수평재화료일개주기후변화유통계학의의(P <0.05)；화료무효조중삼항지표화료후여화료전상비유소변화,단차이균무통계학의의(P >0.05)；삼항지표재단독폐린암급폐선암중적양성솔차이유통계학의의(P <0.05)。결론NSCLC 환자화료과정중감측혈청 Hcy 수평적변화,유조우관찰환자병정동태변화、평고환자화료료효。
Objective To investigate the dynamic change of serum Hcy level in patients with non-small lung cancer when under-going chemotherapy,and to study the value of monitoring serum Hcy for chemotherapy efficieney in non-small-cell carcinoma.Meth-ods In our study,we enrolled 62 patients with non-small-cell carcinoma when undergoing chemotherapy.The concentrations of ho-mocysteine,carcino-embryonic antigen and cytokeratin 1 9 fragments were detected,and then these results were analyzed by statisti-cal methods.Results Compared with before treatment,the serum homocysteine,carcino-embryonic antigen and cytokeratin 1 9 frag-ments levels in patients who had effective response decreased.After 2 courses of chemotherapy,the levels of the three markers were significantly lower than those detected before chemotherapy (P <0.05).But at the end of the first course,the serum hcy level was significantly lower than that detected before chemotherapy.There was no significant difference in the levels of the serum three markers in non-responders between before and after chemotherapy (P >0.05).The positive rates of the three markers were statisti-cally significant between single lung squamous cell carcinoma and adenocarcinoma of the non-small-cell carcinoma.Conclusion The detection of the dynamic changes of serum Hcy in patients with non-small-cell carcinoma when undergoing chemotherapy is useful in evaluating the effect of chemotherapy and tumor activity.